Alloreactive conventional T cell (Alloreactive Tconv)

Alloreactive conventional T cells are a subset of T lymphocytes that recognize non-self human leukocyte antigens (HLA) on donor or recipient tissues, serving as the primary mediators of transplant-related complications. This recognition occurs through the T cell receptor (TCR) via direct, indirect, or semi-direct pathways, where the T cell identifies foreign MHC molecules or donor-derived peptides (PubMed: 30104343). In hematopoietic stem cell transplantation, donor-derived alloreactive T cells drive graft-versus-host disease (GVHD) by attacking host organs, while in solid organ transplantation, recipient alloreactive T cells lead to graft rejection (NIH: NBK538230). These cells are characterized by rapid proliferation and the secretion of pro-inflammatory cytokines like interferon-gamma and TNF-alpha upon activation. Therapeutic strategies focus on the selective depletion or functional inhibition of these cells to prevent tissue damage while attempting to preserve general immunity. Common pharmacological interventions include calcineurin inhibitors like tacrolimus, costimulation blockers like abatacept, and T-cell depleting antibodies such as anti-thymocyte globulin (StatPearls: NBK538230).

Other names

Alloreactive T lymphocyteDonor T cellHLA-reactive T cellAllospecific T cellHLA-mismatched T cell

Therapeutic agents target these cells by inhibiting calcineurin-mediated signaling to prevent IL-2 production, blocking costimulatory pathways (e.g., CD28-CD80/86), inducing direct cell depletion via antibody-dependent cellular cytotoxicity, or selectively eliminating proliferating clones through DNA alkylation during the early post-transplant period.